Recorded device evidence

SAFETY BIOPSY NEEDLE SYSTEM (K140137): indications, design and recorded evidence

The acquired K140137 file contains product-specific indications and users, design and operating principle, performance evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 10 selected decisions under primary code FCG. 10 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

No quartiles are displayed: this complete-year cohort has fewer than 20 valid pairs.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K140137 ↗ · this pageSAFETY BIOPSY NEEDLE SYSTEM2014-01-22 → 2014-03-2562Traditional
K252646 ↗Single-Use Fine Needle Biopsy (FNB) device (NA-U210H)2025-08-21 → 2025-10-2464Traditional
K250994 ↗ClearTip FNA and FNB Types2025-04-01 → 2025-08-21142Traditional
K241209 ↗EchoTip AcuCore™ EUS Biopsy Needle (ECHO-BX-19)2024-04-30 → 2024-07-2990Traditional
K231422 ↗Precision GI2023-05-17 → 2023-08-28103Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K140137 · PDF page 6 ↗ Source 2

The       Safety       Biopsy       Needle      System       (Safety        Biopsy   Needle        and     Safety     Coaxial
                     Needle with     Finger      Guard)            is intended         to    be     used         for soft   tissue    and    tumor
                     biopsy   of  such     organs   as     the       liver,  spleen,          kidney,    prostate,         lung,         breast,     and
                     lymph       nodes.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K140137 · PDF page 1 ↗ Source 3

The         Safety     Biopsy         Needle      System         consists     of  two       main        components:        The          Safety      Biopsy      Needle       and      theSafety     Coaxial        Needle      with        Finger      Guard.

The          Safety      Biopsy         Needle     is composed      of two        primary        assemblies:      the      biopsy     needle        and    the      safety
mechanism.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Performance evidence actually described

K140137 · PDF page 2 ↗ Source 4

Performance      testing     of   the         Safety      Biopsy        Needle      System         was      conducted      in accordance      with      the      following
international        standards:
              "Guidance                         on          Premarket          Notification      [51 0(k)]        for      Medical         Devices      with         Sharps        Injury     Prevention
                   Features;          Guidance     for         Industry    and        FDA.

Compare with your product: The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK140137 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categorySAFETY BIOPSY NEEDLE SYSTEM [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantPfm Medical, Inc. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeFCG [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2014-03-25 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeTraditional [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2014-01-22 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Performance evidence actually described — what differs in our product?

    The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

    Useful evidence: The cited narrative and full tables, underlying protocols/results and a reviewed comparison with the proposed product.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[74004] · record 244dd4226f34e530eb074e1c8b476b4b84c4c88f2f58dfdc2e6ccc6a569e94e4
  • [5] Complete results array / fda-decision-context:K140137 · record whole dataset partition

FDA 510(k) summary — K140137 ↗

Thu, 10 Apr 2014 14:16:07 GMT · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot b2d14a440aa19320f3e862a2738d9d8ec79779ee843603552670130b76d0c625

  • [2] PDF page 6 · record 6a8ff535ae55175a04ca7c73f94f8a3ada9252a3ba5e7a61071f72b5b47c8114
  • [3] PDF page 1 · record 220c80ffdcf93e954d50a70ddd30c66f2c9e3a8434c5925aa25cf67c7a4fc624
  • [4] PDF page 2 · record d7ca3d7d514db84e560b1f9a2a08e24c00384e30fb196857e3723b75d9a36136

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services